181 related articles for article (PubMed ID: 25198900)
21. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Paolicchi E; Vivaldi C; De Gregorio V; Crea F; Fornaro L; Masi G; Loupakis F; Graziano F; Ronzoni M; Ricci V; Falcone A; Danesi R
Oncology; 2016; 91(5):283-288. PubMed ID: 27577551
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E
Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892
[TBL] [Abstract][Full Text] [Related]
24. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
25. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
Choueiri MB; Shen JP; Gross AM; Huang JK; Ideker T; Fanta P
PLoS One; 2015; 10(6):e0126898. PubMed ID: 26083491
[TBL] [Abstract][Full Text] [Related]
27. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
[TBL] [Abstract][Full Text] [Related]
28. Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features.
Azzoni C; Bottarelli L; Cecchini S; Ziccarelli A; Campanini N; Bordi C; Sarli L; Silini EM
Pathol Res Pract; 2014 Feb; 210(2):111-7. PubMed ID: 24332575
[TBL] [Abstract][Full Text] [Related]
29. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
30. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
31. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
[TBL] [Abstract][Full Text] [Related]
32. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
33. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
34. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
[TBL] [Abstract][Full Text] [Related]
36. Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.
Conradi LC; Bleckmann A; Schirmer M; Sprenger T; Jo P; Homayounfar K; Wolff HA; Rothe H; Middel P; Becker H; Ghadimi MB; Beissbarth T; Liersch T
Ann Surg Oncol; 2011 Sep; 18(9):2442-52. PubMed ID: 21347782
[TBL] [Abstract][Full Text] [Related]
37. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Capello M; Lee M; Wang H; Babel I; Katz MH; Fleming JB; Maitra A; Wang H; Tian W; Taguchi A; Hanash SM
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025324
[TBL] [Abstract][Full Text] [Related]
38. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
[TBL] [Abstract][Full Text] [Related]
39. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
Palshof JA; Cederbye CN; Høgdall EVS; Poulsen TS; Linnemann D; Nygaard SB; Stenvang J; Christensen IJ; Jensen BV; Pfeiffer P; Brünner N; Yilmaz M; Viuff BM; Nielsen DL
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708825
[TBL] [Abstract][Full Text] [Related]
40. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Aschele C; Debernardis D; Tunesi G; Maley F; Sobrero A
Clin Cancer Res; 2000 Dec; 6(12):4797-802. PubMed ID: 11156237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
